Bioequivalence Between Generic and Branded Lamotrigine in People With Epilepsy: The EQUIGEN Randomized Clinical Trial

IMPORTANCE: Switching between generic antiepileptic drugs is a highly debated issue that affects both clinical care and overall health care costs. OBJECTIVE: To evaluate the single-dose pharmacokinetic bioequivalence of 3 (1 branded and 2 generic drugs) on-market, immediate-release lamotrigine drug...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:JAMA Neurol
Glavni autori: Berg, Michel, Welty, Timothy E., Gidal, Barry E., Diaz, Francisco J., Krebill, Ron, Szaflarski, Jerzy P., Dworetzky, Barbara A., Pollard, John R., Elder, Edmund J., Jiang, Wenlei, Jiang, Xiaohui, Switzer, Regina D., Privitera, Michael D.
Format: Artigo
Jezik:Inglês
Izdano: American Medical Association 2017
Teme:
Original Investigation
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5710324/
https://ncbi.nlm.nih.gov/pubmed/28654954
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaneurol.2017.0497
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items